Stock listing

Stockholm:EXPRS2 ExpreS2ion Biotech Holding AB Aktie

Home listing (Stockholm) of ExpreS2ion Biotech Holding AB

Follow ExpreS2ion Biotech Holding AB into a list and get an email when it puts out news.

Share price · OMXSTO:EXPRS2

0.82 SEK -0.13 (-13.7%)

Close on Nov 20, 2026

Past year -87.2% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
0.61 – 1.00 SEKNov 20, 2026
Volume
279,511 sharesNov 20, 2026
Market cap
8.10M SEKAt the close on Nov 20, 2026 · price × 9.88M shares outstanding
52-week range
0.61 – 6.63 SEKLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
116,500 SEKMedian day 63,977 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
ExpreS2ion Biotech Holding AB logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
Stockholm:EXPRS2 · Home0.82 SEK-0.13 (-13.7%)279,5111.001.000.610.95Close on Nov 20, 2026
Frankfurt:5JD0€0.043 EUR-0.012 (-21.8%)—€0.055€0.055€0.043€0.055Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OMXSTO:EXPRS2 · SEK, adjusted for splits

DayCloseChange%OpenHighLowVolume
0.82-0.13-13.7%1.001.000.61279,511
0.95-0.048-4.8%1.0051.0050.93101,249
0.998+0.058+6.2%0.9661.040.966163,056
0.94-0.05-5.1%0.990.990.93255,947
0.99+0.03+3.1%0.971.000.914152,416
0.96-0.03-3.0%0.9141.000.90224,596
0.99+0.062+6.7%1.011.010.91412,659
0.928-0.072-7.2%0.981.050.90116,018
1.000.000.0%1.0251.060.976123,999
1.000.000.0%1.001.010.9440,047
1.00+0.008+0.8%0.991.000.9349,682
0.992+0.058+6.2%0.9361.000.9064,529
0.9340.000.0%0.9340.950.93436,006
0.934-0.096-9.3%0.9981.010.934117,309
1.03-0.01-1.0%1.041.040.9620,299
1.04+0.05+5.1%1.001.0450.92877,809
0.99-0.06-5.7%1.051.050.90307,308
1.05-0.03-2.8%1.0151.1050.98264,441
1.08+0.02+1.9%0.9781.080.96846,533
1.060.000.0%1.061.070.96816,809
1.06+0.04+3.9%1.001.061.0028,020
1.02-0.01-1.0%0.9661.0450.95626,676
1.030.000.0%0.981.060.96630,117
1.030.000.0%0.9021.030.88292,957
1.03-0.06-5.5%1.091.090.914146,931
1.09+0.01+0.9%1.0951.0951.0374,702
1.08-0.01-0.9%1.091.141.0278,301
1.09+0.035+3.3%1.041.151.0465,645
1.055-0.005-0.5%1.061.060.98253,473
1.06-0.065-5.8%1.1251.1251.0429,230
1.125+0.005+0.4%1.131.131.0985,393
1.12+0.025+2.3%1.121.1251.0853,873
1.095-0.07-6.0%1.1051.151.08162,264
1.165-0.025-2.1%1.1951.1951.13537,655
1.19+0.025+2.1%1.1651.201.09140,322
1.165+0.05+4.5%1.081.1651.0750,192
1.115-0.015-1.3%1.131.1351.08537,111
1.13+0.005+0.4%1.1151.151.0841,912
1.125-0.055-4.7%1.171.171.0473,211
1.18-0.025-2.1%1.2051.2351.1840,671
1.205-0.025-2.0%1.2351.2351.19572,526
1.23-0.09-6.8%1.321.321.2170,631
1.32+0.02+1.5%1.301.321.2439,187
1.30-0.03-2.3%1.2251.3251.22528,716
1.33+0.005+0.4%1.3451.391.27563,425
1.325+0.075+6.0%1.2951.401.29201,136
1.250.000.0%1.251.301.20533,844
1.25-0.005-0.4%1.2151.3551.21522,555
1.255-0.03-2.3%1.2851.2851.20574,080
1.285-0.065-4.8%1.3051.3251.28515,547
1.350.000.0%1.291.371.2954,480
1.35+0.005+0.4%1.371.371.28535,265
1.345-0.05-3.6%1.321.3751.2947,307
1.395+0.065+4.9%1.331.401.25158,636
1.33-0.085-6.0%1.3251.411.2733,613
1.415+0.11+8.4%1.301.4151.25576,290
1.305+0.005+0.4%1.301.311.23587,583
1.30+0.055+4.4%1.2451.301.2134,418
1.245-0.035-2.7%1.2751.291.15338,627
1.28-0.10-7.2%1.3951.3951.10546,063
1.38+0.04+3.0%1.3351.401.30174,168
1.34-0.06-4.3%1.401.401.30549,385
1.40+0.015+1.1%1.4451.4451.325362,557
1.385-0.01-0.7%1.4251.491.31223,360

Splits

1 split · OMXSTO:EXPRS2 · every price before a split is adjusted for it

DayRatioWhat
1-for-40Consolidation
Ticker
Stockholm:EXPRS2
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
Stockholm
Currency
SEK

What changed lately

Latest news

All ExpreS2ion Biotech Holding AB news

ExpreS2ion Biotech Holding AB on 6ix

Sector
Health care
Industry
Biotechnology
News releases
12 in the last 12 months · 12 in all · newest Sep 14, 2026 · oldest 2026
Calls
10 calls with a replay · 10 with a transcript · latest Aug 20, 2026
Decks
53 decks · latest Nov 12, 2026

Where ExpreS2ion Biotech Holding AB is listed

ListingExchangeCountryCurrency
Stockholm:EXPRS2 · Home listing · This pageStockholmSwedenSEK
LS Exchange:A40P4HLS ExchangeGermanyEUR
Lang & Schwarz:A40P4HLang & SchwarzGermanyEUR
gettex:5JD0gettexGermanyEUR
Stuttgart:5JD0StuttgartGermanyEUR
Frankfurt:5JD0FrankfurtGermanyEUR
Munich:5JD0MunichGermanyEUR

Valuation

EV/sales −6.5× against a median of 42.8×: the lowest of 2 Biotechnology companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
−24.82M SEK
P/E
Loss
EV/sales
−6.5×
EV/EBITDA
Negative EBITDA
Price/book
0.2×
Gross margin
Revenue too small
Operating margin
Revenue too small
Net margin
−935.9%
Debt to equity
0.0×
Beta
No index for this market yet

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
ExpreS2ion Biotech Holding AB · OMXSTO:EXPRS2US$794,844−US$2.43Mn/a−6.5×n/a0.2×−935.9%0.0×n/a
SureNano Science Ltd · CSE:SUREUS$1.17MUS$672,321n/an/an/a0.3×n/a0.0×0.25
Valion Bio, Inc. · NASDAQ:VBIOUS$1.04MUS$16.34Mn/a42.8×n/a0.2×n/a4.1×1.11
GeoVax Labs, Inc. · NASDAQ:GOVXUS$985,460−US$915,033n/an/an/a0.9×n/a0.2×1.47
Biodexa Pharmaceuticals plc · NASDAQ:BDRXUS$982,950−US$3.22Mn/an/an/a0.1×n/a0.0×1.01
Gabather AB · OMXSTO:GABAUS$922,076US$560,663n/an/an/a6.4×n/a0.0×n/a
Silexion Therapeutics Corp · NASDAQ:SLXNUS$790,001−US$3.60Mn/an/an/a0.3×n/a0.1×2.77
Oragenics Inc. · AMEX:OGENUS$708,377−US$1.12Mn/an/an/a0.7×n/a0.4×1.47
Protagenic Therapeutics, Inc. · OTC:PTIXUS$687,879US$610,9700.1×n/an/a0.6×n/a0.0×1.21
Lakewood-Amedex Biotherapeutics Inc. · NASDAQ:LABTUS$580,337−US$2.74Mn/an/an/a0.2×n/a0.0×0.46
Mushrooms, Inc. · OTC:MSRMUS$539,339US$564,177n/an/an/an/an/an/a1.24
Median of the othersUS$856,039−US$177,1850.1×42.8×0.3×0.0×1.21

Forecasts

Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
4.00 SEK · Analysts' mean
EPS, year to Dec 2026
-22.87 · 1 analyst
Revenue, year to Dec 2026
30.4M · 1 analyst

Team and board

Officers

OfficerRole
Bent U. FrandsenChief Executive Officer
Keith AlexanderChief Financial Officer
Max M. SøgaardChief Scientific Officer

Board

DirectorRole
Martin Roland JensenChairman
Jakob KnudsenBoard Member
Karin GarreBoard Member
Michel BaijotBoard Member

Events

Next results
Feb 25, 2027 (expected)

Results days

QuarterResultsShare move
Quarter to Sep 30, 2026Nov 12, 2026 · After close+3.1%
Q2 2026Aug 20, 2026 · After close+1.1%
Q1 2026May 28, 2026 · After close0.0%
Q4 2025Feb 19, 2026 · After close−2.1%
Q1 2025May 15, 2025 · Before open−3.1%
Q4 2024Feb 6, 2025 · Before open−1.3%
Q3 2024Nov 14, 2024 · Before open−7.1%
Q2 2024Aug 15, 2024 · Before open+4.0%
Q1 2024May 16, 2024 · Before open−1.3%
Q4 2023Feb 8, 2024 · Before open+0.9%
All 20 quarters
QuarterResultsShare move
Q3 2023Nov 16, 2023 · Before open+17.7%
Q2 2023Aug 17, 2023 · Before open−4.1%
Q1 2023May 16, 2023 · Before open−2.9%
Q4 2022Feb 9, 2023 · Before open+3.0%
Q3 2022Nov 17, 2022 · Before open−4.5%
Q2 2022Aug 18, 2022 · Before open+1.0%
Q1 2022May 31, 2022 · Before open−3.8%
Q4 2021Feb 24, 2022 · Before open−13.1%
Q3 2021Nov 15, 2021 · Before open+1.3%
Quarter to Jun 30, 2021Jul 28, 2021 · Before open+3.9%

Open Events

Decks

DeckKindSlidesDate
Q3 2026 Earnings PresentationEarnings24 slidesNov 12, 2026
Investor Presentation (October 2026)Investor deck9 slidesOct 7, 2026
Q2 2026 Earnings PresentationEarnings23 slidesAug 20, 2026
Q1 2026 Earnings PresentationEarnings21 slidesMay 28, 2026
Q1 2026 Earnings PresentationEarnings24 slidesMay 28, 2026
BioStock Global Forum 2026Conference9 slidesMay 21, 2026
ØU Life Science Investor Konference 2026Conference16 slidesMar 25, 2026
Sachs European Life Science Forum 2026Conference9 slidesMar 5, 2026
Q4 2025 Earnings PresentationEarnings18 slidesFeb 19, 2026
Redeye Fight Cancer 2026Conference18 slidesJan 21, 2026
Show 50 decks
DeckKindSlidesDate
Redeye Life Science Day 2025Conference17 slidesDec 3, 2025
Q3 2025 Earnings PresentationEarnings21 slidesNov 13, 2025
BioStock Life Science Summit 2025Conference13 slidesNov 13, 2025
Q3 2025 Earnings PresentationEarnings31 slidesNov 13, 2025
BioStock: Investing in Life Science 2025Conference13 slidesSep 23, 2025
H.C. Andersen Capital Institutional Seminar (September 2025)Conference13 slidesSep 18, 2025
Aktiespararna Aktiedagen (September 2025)Conference23 slidesSep 16, 2025
Investor Day (August 2025)Investor day21 slidesAug 29, 2025
Økonomisk Ugebrev Life Science Investor Conference August 2025Conference17 slidesAug 27, 2025
H1 2025 Earnings PresentationEarnings22 slidesAug 21, 2025
Q1 2025 Earnings PresentationEarnings21 slidesMay 15, 2025
Q3 2024 Earnings PresentationEarnings27 slidesNov 14, 2024
Q2 2024 Earnings PresentationEarnings24 slidesAug 15, 2024
BioStock Global Forum 2024Conference15 slidesMay 30, 2024
Q1 2024 Earnings PresentationEarnings24 slidesMay 16, 2024
FY2023 Earnings PresentationEarnings22 slidesFeb 8, 2024
Redeye Theme: Fight Cancer 2024Conference13 slidesJan 24, 2024
Økonomisk Ugebrev Life Science Investor Conference (November 2023)Conference23 slidesNov 22, 2023
Q3 2023 Earnings PresentationEarnings24 slidesNov 16, 2023
H.C. Andersen Capital Life Science Seminar 2023Conference16 slidesAug 31, 2023
H1 2023 Earnings PresentationEarnings17 slidesAug 17, 2023
Aktiespararna Småbolagsdagarna (June 2023)Conference19 slidesJun 13, 2023
Q1 2023 Earnings PresentationEarnings19 slidesMay 16, 2023
ØU Life Science Investor Konference 2023Conference22 slidesApr 19, 2023
Rights Issue Webinar hosted by HC Andersen Capital (March 2023)Conference11 slidesMar 31, 2023
Q4 2022 Earnings PresentationEarnings24 slidesFeb 15, 2023
BioStock Life Science Summit 2022Conference17 slidesNov 30, 2022
Q3 2022 Earnings PresentationEarnings21 slidesNov 17, 2022
Aktiespararna's Aktiedagen, Lund 2022Conference16 slidesSep 26, 2022
Q1 2022 Earnings PresentationEarnings16 slidesJun 9, 2022
Virtual Oncology Webinar hosted by H.C. Andersen Capital (May 2022)Conference12 slidesMay 31, 2022
Økonomisk Ugebrev Life Science Investor Conference (April 2022)Conference22 slidesApril 2022
Aktiespararna's Aktiedagen Stockholm 2022Conference23 slidesMar 14, 2022
Q4 2021 Earnings PresentationEarnings21 slidesFeb 24, 2022
Nordea and H.C. Andersen Capital Virtual Growth Days 2021Conference7 slidesDec 9, 2021
Aktiespararna's Aktiedagen Stockholm 2021Conference27 slidesDec 2, 2021
Q3 2021 Earnings PresentationEarnings16 slidesNov 18, 2021
ØU Life Science Investor Conference (September 2021)Conference22 slidesSep 22, 2021
Aktiespararna's Aktiedagen Stockholm 2021Conference27 slidesSep 7, 2021
Q2 2021 Earnings PresentationEarnings15 slidesAug 19, 2021

This page holds 50 of 53 decks. Open Decks

Open Decks

Financings

RaiseDateIn US dollars
New shares on exercise of TO 13 warrants and directed issue to guarantor
Announced: SEK 19.3M–SEK 32.4M · SEK 1.6 a share · Vator Securities +2
Dealers: Vator Securities, SCHMIDT Capital Advisors, APREA Partners
Buyers: Vator Securities (guarantee undertaking totalling SEK 19.3 million); Alumni Capital; Tellus Equity AB; Leif Helth Jensen; John Haurum; Thomas Larsson
Use of proceeds: Complete the ES2B-C001 Phase I study, strengthen licensing negotiations, platform and CMC development, and business development
Sep 14, 2026US$1.98M
New shares under put option agreement
Announced: up to SEK 50M
Buyers: Alumni Capital Limited (commitment of up to SEK 50,000,000 in equity financing over 24 months)
Sep 14, 2026US$5.12M
Rights offering of units consisting of new shares and warrants of series TO 13
Closed: SEK 31.8M raised · SEK 1.6 a unit · warrants of series TO 13 issued free of charge, exercisable at a price corresponding… · Schmidt Capital Advisors +1
Dealers: Schmidt Capital Advisors, Vator Securities
Buyers: Bent U. Frandsen (part of board and management subscription commitments totalling approximately SEK 0.7 million)
Insiders: Board members and management, including CEO Bent U. Frandsen, gave subscription commitments totalling approximately SEK 0.7 million, about 1.3 percent of the Rights Issue
Use of proceeds: Continue executing the prioritised strategy and support the Company through the period leading up to the TO 13 warrant exercise window
May 4, 2026US$3.43M

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in SEK

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue3.66M3.01M7.05M5.09M12.2M5.26M13.8M8.87M9.79M4.65M
Cost of revenue46.5M5.68M3.65M5.08M7.51M6.10M3.40M2.75M2.19M1.35M
Gross profit-42.8M-2.67M3.40M5.00K4.72M-843.0K10.4M6.12M7.60M3.30M
Research and development9.98M26.7M51.4M71.3M9.81M216.0K
Selling, general and administrative27.0M27.0M43.3M41.3M3.52M21.4M8.54M7.18M5.93M4.17M
Operating income-52.8M-67.7M-106.0M-127.6M-48.4M-31.2M-16.3M-18.3M-11.4M-9.16M
Depreciation and amortization1.47M1.64M1.60M1.22M1.81M2.92M2.88M2.62M2.28M1.49M
EBITDA-51.4M-66.1M-104.4M-126.4M-46.6M-28.3M-13.4M-15.6M-9.15M-7.67M
Interest expense451.0K727.0K501.0K871.0K156.0K3.53M971.0K617.0K461.0K557.0K
Income before tax-44.2M-44.6M-100.0M-126.6M-47.5M-34.9M-19.1M-18.9M-11.8M-9.41M
Income tax-6.09M-8.53M-8.57M-7.98M-3.59M-3.21M-2.38M-2.03M-1.92M-874.0K
Net income-38.1M-36.0M-91.4M-118.6M-43.9M-31.7M-16.7M-16.8M-9.84M-8.54M
Earnings per share, basic-13.39-13.88-79.22-125.71-1.36-1.66-1.03-1.14-0.81-30.07

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents47.6M81.5M57.6M111.0M37.1M106.8M5.42M6.25M1.51M6.26M
Short-term investments4.44M-1.53M101.8M-966.0K-933.0K-682.0K
Receivables9.97M5.06M2.35M10.8M7.11M5.10M4.35M4.05M4.21M5.31M
Inventory-4.05M-4.21M1
Current assets57.5M95.0M68.7M131.9M146.5M112.5M10.1M10.8M6.05M11.8M
Property, plant and equipment465.0K1.53M1.77M910.0K1.21M1.29M1.19M993.0K632.0K679.0K
Goodwill016.0K00194.0K802.0K1.38M1.90M2.40M
Total assets65.1M104.5M78.7M137.4M152.0M118.9M18.7M21.0M17.2M24.6M
Accounts payable4.04M8.47M1.84M12.2M1.69M2.08M1.08M607.0K470.0K799.0K
Current liabilities28.3M38.2M11.4M31.4M7.46M18.2M12.2M5.04M2.36M3.58M
Long-term debt3.48M5.27M6.38M6.06M6.32M
Total debt2.21M1.80M1.71M1.85M5.39M7.16M7.87M6.99M6.40M5.87M
Total liabilities29.4M40.1M13.3M34.0M11.6M24.3M19.8M12.7M10.5M11.7M
Shareholders' equity35.7M64.8M65.4M103.3M140.3M94.5M-1.08M8.30M6.74M12.9M
Shares outstanding2.84M2.60M1.15M943.5K32.2M19.1M16.2M14.7M12.2M283.9K

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-40.9M-33.9M-100.9M-99.6M-45.6M-18.2M-12.7M-12.9M-8.61M-7.02M
Capital spending0-870.0K-2.02M-383.0K-715.0K-885.0K-679.0K-813.0K-206.0K-720.0K
Free cash flow-40.9M-34.8M-102.9M-100.0M-46.4M-19.1M-13.4M-13.7M-8.81M-7.74M
Cash from investing021.3M-2.02M105.3M-100.9M-1.08M-679.0K-813.0K-206.0K-720.0K
Cash from financing10.8M34.9M47.8M61.5M74.5M123.4M12.6M18.6M3.98M14.7M
Share buybacks12.1M42.3M60.7M76.0M83.3M143.2M8.00M19.3M-402.0K-2.11M
Change in cash-34.0M23.9M-53.4M73.9M-69.7M101.4M-837.0K4.75M-4.75M5.94M

Open Financials

Cap table

Built by 6ix from ExpreS2ion Biotech Holding AB’s releases · as of Sep 14, 2026

Common shares
9,883,280
Fully diluted
9,883,280

Fully diluted

LineShares
Common shares9,883,280

Warrants and options

Lot
Warrants · expiry not stated

Share count over time

CountShares
Nov 22, 20269,883,280

Open Cap table

Shareholders

InsiderTradeSharesPriceValueDate
Bent Frandsen
Chief Executive Officer (CEO)/Managing Directory
Buy10,000SEK 1.10SEK 11,000Oct 9, 2026
Bent Frandsen
Chief Executive Officer (CEO)/Managing Directory
Buy10,000SEK 1.10SEK 11,000Oct 9, 2026
Bent Frandsen
Chief Executive Officer (CEO)/Managing Directory
Buy8,000SEK 1.15SEK 9,200Oct 2, 2026
Bent Frandsen
Chief Executive Officer (CEO)/Managing Directory
Buy12,000SEK 1.19SEK 14,280Oct 1, 2026
Jakob Knudsen
Member of the Board of Directors
Buy89,407SEK 1.60SEK 143KMay 6, 2026
Martin Roland Holding ApS
Chairman of the Board of Directors
Buy93,750SEK 1.60SEK 150KApr 30, 2026
Keith Alexander
Chief Financial Officer (CFO)
Buy12,500SEK 1.60SEK 20,000Apr 30, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Bent U. FrandsenChief Executive Officer · Since at least Sep 14, 2026
Jakob KnudsenBoard Member · Since at least Nov 5, 2026
Karin GarreBoard Member · Since at least Nov 5, 2026
Keith AlexanderChief Financial Officer · Since at least Sep 14, 2026
Martin Roland JensenChairman · Since at least Nov 5, 2026
Max M. SøgaardChief Scientific Officer · Since at least Nov 4, 2026
Michel BaijotBoard Member · Since at least Aug 20, 2026

Open People

Log in to ask 6ix AI your own questions about ExpreS2ion Biotech Holding AB.